Thera-SAbDab

LORVOTUZUMAB

>   Structural Summary
TherapeuticLorvotuzumab
TargetNCAM1
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS
Light ChainDVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG1
Highest Clinical Trial (August '23)Phase-II
Estimated Status (August '23)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedImmunoGen
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMultiple myeloma, Solid tumours, Small cell lung cancer, Haematological malignancies
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy